Anuh Pharma Limited announced Q1 financial results with revenue from operations increasing by 35.2% year-over-year to Rs 18,647.94 lakhs. However, profit after tax decreased slightly to Rs 830.12 lakhs. The company's EBITDA margin declined to 7.34% from 10.36% in the previous year. Additionally, Anuh Pharma appointed Mr. Vinayak Shenoy as Chief Marketing Officer, effective August 11, 2025, bringing over 15 years of experience in APIs and Intermediates across global markets.
15Jul 25
Anuh Pharma Boosts Production Capacity with New Manufacturing Facility in Tarapur
Anuh Pharma Limited has inaugurated a new manufacturing facility, Manufacturing Block INT-1A, in Tarapur, Maharashtra. The facility, opened on July 15, 2025, will increase the company's production capacity by 200 MT/Annum, bringing the total to approximately 2,400 MT/Annum. The expansion includes an additional 40 KL of reactor capacity, enhancing the company's infrastructure to meet growing market demands in the pharmaceutical sector.
Anuh Pharma Ltd. released its Q4 FY2023-24 results, showing a 15.85% increase in revenue to ₹1,900 crore. However, net profit declined by 18.62% to ₹125 crore. The company's EBITDA margin contracted to 10.48%. Despite Q4 challenges, annual performance for FY2024 was strong with a 23.52% revenue growth and 66.02% increase in net profit. The board recommended a dividend of ₹1.50 per equity share.